Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coagulation monitoring system for emicizumab prophylaxis in pediatric hemophilia A
ChiCTR2300068826Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Oct 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Beijing Children's Hospital. Primary endpoints: Annual bleeding rate, Joint function and 2 more. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on ChiCTR2300068826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068826.